The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co’s blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their tumors removed surgically.

The U.S. health regulator’s approval extends Keytruda’s use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients.